Efficacy and Safety of Nepcell STM to Achieve Hemostasis after Removal of a 15-French Caliber Femoral Venous Sheath in Patients Undergoing Cryoballoon Ablation of Atrial Fibrillation.

Efficacy and Safety of Nepcell STM to Achieve Hemostasis after Removal of a 15-French Caliber Femoral Venous Sheath in Patients Undergoing Cryoballoon Ablation of Atrial Fibrillation. - Efficacy of Nepcell STM for Hemostasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044940

Enrollment

100

Registered

2021-07-22

Start date

2021-07-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

Nepcell group conterol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with non-valvular paroxysmal AF were admitted to our hospital to undergo cryoballoon ablation for AF.

Exclusion criteria

Exclusion criteria: HD

Design outcomes

Primary

Measure	Time frame
time to hemostasis	—

Secondary

Measure	Time frame
internal hemorrhage, re-bleeding, duration of hospital stay, and 1-month vascular complications	—

Countries

Japan

Contacts

Public ContactMasao Takemoto

Steel Memorial Yawata Hospital Cardiovascular Center

matakemo@kc4.so-net.ne.jp093-672-3176

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026